Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: Systematic reviews of effectiveness, modelling study and national survey of current practice

Health Technology Assessment

Volumn 6, Issue 31, 2002, Pages

  Stein, Ken ^a   Dalziel, K ^a   Walker, A ^b   McIntyre, L ^a   Jenkins, B ^c   Horne, J ^d   Royle, P ^e   Round, A ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c North and East Devon Health Authority   (United Kingdom)

^d South and West Devon Health Authority   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT;

CHRONICITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DATA BASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; MEDICAL PRACTICE; NATIONAL HEALTH SERVICE; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SCREENING; SCREENING TEST; SEXUAL TRANSMISSION; UNITED KINGDOM; UROGENITAL SYSTEM; VIRUS TRANSMISSION;

EID: 0036919878     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Edeh J, Spalding P. Screening for HIV, HBV and HCV markers among drug users in treatment in rural south-east England. J Public Health Med 2000;22:531-9.
2. Newell A, Watson-Jones D, Evans BA, Barton SE. Screening for hepatitis B, hepatitis C and syphilis at two genitourinary medicine clinics. Int J STD AIDS 1995;6:59-60.
3. Butler T, Dolan K, Ferson M, McGuiness L, Brown P. Hepatitis B and C in New South Wales prisons: Prevalence and risk factors. Med J Aust 1997;166:127-30.
4. Ward C, Tudor-Williams G, Cotzias T, Hargreaves S, Regan L, Foster GR. Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: Uptake and acceptability of named antenatal testing. Gut 2000;47:277-80.
5. Seymour CA. Screening asymptomatic people at high risk for hepatitis C. The case for. BMJ 1996;312:1347-8.
6. Allison MC, Mills PR. Screening asymptomatic people at high risk for hepatitis C. The case against. BMJ 1996;312:1349-50.
7. European Association for the Study of the Liver (EASL). EASL International Consensus Conference on Hepatitis C. J Hepatol 1999;30:956-61.
8. Centre for Disease Control. Recommendations for the prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998;47:1-39.
9. American Academy of Pediatricians. Hepatitis C virus infection. Pediatrics 1998;101:481-5.
10. Galmiche JP. French consensus conference on hepatitis C: Screening and treatment. Gut 1998;42:892-8.
11. National Institutes for Health. Management of hepatitis C. NIH Consensus Development Reports 1997;15:1-41.
12. The Advisory Council on the Misuse of Drugs. Reducing Drug Related Deaths. London: The Stationary Office; 2000.
13. Department of Health. The Government Response to the Advisory Council on the Misuse of Drugs Report Into Drug Related Deaths. London: Department of Health; 2001.
14. Department of Health, Scottish Office, Home and Health Department WO, Department of Health and Social Services NI. Drug Misuse and Dependence: Guidelines for Clinical Management. London: The Stationary Office; 1999.
15. Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J. Reply to: Value of screening for hepatitis C is still debatable. BMJ 2000;320:512.
16. Wilson J, Jungner G. Principles and Practice of Screening. Geneva: World Health Organization; 1968.
17. National Screening Committee. The Second Report of the National Screening Committee. London: Department of Health; 2000.
18. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
19. Goldberg D, Cameron S, McMenamin J. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high. Commun Dis Public Health 1998;1:95-7.
20. National Institute for Clinical Excellence. Guidance on the Use of Ribavirin and Interferon Alpha for Chronic Hepatitis C. London: NICE; 2000.
21. Stein K, Rosenberg W, Wong JB. Cost effectiveness of combination therapy for hepatitis C: A decision analytic model. Gut 2002;50:253-8.
22. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: Knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend 2002;61:211-15.
23. Harris KA, Gilham C, Mortimer PP, Teo CG. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J Med Virol 1999;58:127-31.
24. Seeff LB. Natural history of hepatitis C. Am J Med 1999;107:10S-11S.
25. Management of hepatitis C. NIH Consensus Statement 1997;15:1-41.
26. International Interferon-alpha Hepatocellular Cancer Study Group. Effect of inte.rferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study. Lancet 1998;351:1535-9.
27. Naoumov NV, Haigh P. Strategies to prevent progression to cirrhosis and hepatocellular carcinoma. In: Dusheiko GM, Rosenberg W, Miles A, editors. The Effective Management of Hepatitis C. London: Aesculapius Medical Press; 2001. p 121-30.
28. Gordon SC, Elloway RS, Long JC, Dmuchowski CF. The pathology of hepatitis C as a function of mode of transmission: Blood transfusion vs. intravenous drug use. Hepatology 1993;18:1338-43.
29. Pozzato G, Moretti M, Franzin F, Croce LS, Tiribelli C, Masayu T et al. Severity of liver disease with different hepatitis C viral clones. Lancet 1991;338(8765):509.
30. McQuillan G, Alter MJ, Moyer LA, Lambert S, Margolis H. A population based serologic study of hepatitis C virus infection in the United States. In: Rizzetto M, Purcell R, Gerin J, Verme G, editors. Viral Hepatitis and Liver Disease. Turin: Edizioni Minerva Medica; 1997. p 267-70.
31. Ramsay ME, Balogun MA, Harris HE. Epidemiology and health burden of hepatitis C in the UK. In: Dusheiko G, Rosenberg W, Miles, A, editors. The Effective Management of Hepatitis C. London: Aesculapius Medical Press; 2001. p 15-29.
32. Goldberg D, McIntyre PG, Smith R, Appleyard K, Dunlop J, Taylor A et al. Hepatitis C virus among high and low risk pregnant women in Dundee: Unlinked anonymous testing. Br J Obstet Gynaecol 2001;108:365-70.
33. Boxall E, Skidmore S, Evans C, Nightingale S. The prevalence of hepatitis B and C in an antenatal population of various ethnic origins. Epidemiol Infect 1994;113:523-8.
34. Balogun MA, Ramsay ME, Parry JV, Donovan L, Andrews NJ, Newham JA et al. The prevalence and genetic diversity of hepatitis C infection in antenatal clinic attenders in two regions of England. Epidemiol Infect 2000;125:705-12.
35. Scottish Needs Assessment Program. Hepatitis C, 2000. Glasgow: Office for Public Health in Scotland; 2000.
36. Mohsen AH, Group TH. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001;48:707-13.
37. McLindon JP, Paver WK, Babbs C, Yates AD, McMahon RF, Love EM et al. Hepatitis C-related chronic liver disease among asymptomatic blood donors in the north west of England. J Infect 1995;30:253-9.
38. Public Health Laboratory Service. Surveillance of viral infections in donated blood: England and Wales, 1997. Commun Dis Rep PHLS Central Public Health Laboratory 1998;8:364.
39. Hagan H. Hepatitis C virus transmission dynamics in injection drug users. Subst Use Misuse 1998;33:1197-212.
40. Goldberg D, Taylor A, Hutchinson S, McMenamin J. Hepatitis C infection among injecting drug users in Scotland: Stemming the flow. Scot Med J 2000;45:131-2.
41. Gore SM, Bird AG, Cameron SO, Hutchinson SJ, Burns SM, Goldberg DJ. Prevalence of hepatitis C in prisons: WASH-C surveillance linked to self-reported risk behaviours. QJM 1999;92:25-32.
42. Department of Health. Prevalence Report of the Unlinked Anonymous Prevalence Monitoring Programme. London: Department of Health; 2000. p. 1-32.
43. Weild AR, Gill ON, Bennett D, Livingstone SJ, Parry JV, Curran L. Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: A national survey. Commun Dis Public Health 2000;3:121-6.
44. Durante AJ, Heptonstall J. How many people in England and Wales risk infection from injecting drug use? Commun Dis Rep CDR Rev 1995;5:R40-4.
45. Home Office Research and Statistics Department. Statistics of drug addicts notified to the home office United Kingdom 1993. Home Office Statistics Bull 1994;10.
46. Department of Health. Statistics from the Regional Drug Misuse Databases on Drug Misusers in Treatment in England, 2000/01. London: Department of Health; 2001 Report no.: Statistical Bulletin 33.
47. Johnson AM, Wadsworth J, Wellings K, Field J. Sexual Attitudes and Lifestyles. London: Blackwell Scientific Publications; 1994.
48. Leitner M, Shapland J, Wiles P. Drug Usage and Drug Prevention. London: Her Majesty's Stationary Office; 1993.
49. Osmond DH, Padian NS, Haynes W, Sheppard HW, Glass S, Shiboski SC, et al. Risk factors for hepatitis C virus seropositivity in heterosexual couples. JAMA 1993;269:361-5.
50. Neal KR, Jones DA, Killey D, James V. Risk factors for hepatitis C virus infection. A case-control study of blood donors in the Trent region (UK). Epidemiol Infect 1994;112:595-601.
51. Tedders RS, Gilson RJ, Briggs M, Loveday C, Cameron CH, Garson JA et al. Hepatitis C virus: Evidence for sexual transmission. BMJ 1991;302:1299-1302.
52. Weinstock HS, Bolan G, Reingold AL, Polish LB. Hepatitis C virus infection among patients attending a clinic for sexually transmitted diseases. JAMA 1993;269:392-4.
53. Sulkowski MS. Hepatitis C virus and HIV co-infection: A sleeping giant wakes. Hopkins HIV Rep 1999;11:
54. Goldberg D, Cameron S, Sharp G, Burns S, Scott G, Molyneaux P et al. Hepatitis C virus among genitourinary clinic attenders in Scotland: Unlinked anonymous testing. Int J STD AIDS 2001;12:17-21.
55. Tong MJ, Lai PPC, Hwang SJ, Lee SY, Co RL, Chien RND et al. Evaluation of sexual transmission in patients with chronic hepatitis C infection. Clin Diagn Virol 1995;3:39-47.
56. Lamagni T, Hughes G, Rogers PA, Paine T, Catchpole M. New cases seen at genitourinary medicine clinics: England 1998. CDR Supplement 1999;9:1-12.
57. Department of Health. Compendium of Clinical and Health Indicators 2000. London: Office for National Statistics; 2001.
58. Gunn RA, Murray PJ, Ackers ML, Hardison WGM, Margolis HS. Screening for chronic hepatitis B and C virus infections in an urban sexually transmitted disease clinic: Rationale for integrating services. Sex Transm Dis 2001;28:166-70.
59. Johnson AM, Wadsworth J, Wellings K, Field J. Who goes to sexually transmitted disease clinics? Results from a national population survey. Genitourin Med 1996;72:197-202.
60. Ackerman Z, Ackerman E, Paltiel O. Intrafamilial transmission of hepatitis C virus: A systematic review. J Viral Hepatitis 2000;7:93-103.
61. Touzet S, Kraemer L, Colin C, Pradat P, Lanoir D, Bailly F et al. Epidemiology of hepatitis C virus infection in seven European Union countries: A critical analysis of the literature. HENCORE Group (Hepatitis C European Network for Co-operative Research). Eur J Gastroenterol Hepatol 2000;12:667-78.
62. Carithers RL, Sugano D, Bayliss M. Health assessment for chronic HCV infection: Results of quality of life. Dig Dis Sci 1996;41 Suppl 12:75-80.
63. Patil R, Cotler SJ, Banaad-Oniotek G, McNutt R, Brown M, Cotler S et al. Physicians' preference values for hepatitis C health states and antiviral therapy: A survey. BMC Gastroenterol 2001;1:6.
64. Bonkovsky HL, Woolley JM. Reduction in health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999;29:264-70.
65. Bayliss MS. Methods in outcomes research in hepatology: Definitions and domains of quality of life. Hepatology 1999;29 Suppl 6:3-6.
66. Conroy CG, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-6.
67. Ware JE, Bayliss MS, Mannocchia M, Davis GL, Bassaris H, Batey R et al. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. Hepatology 1999;30:550-5.
68. Ware JE, Snow KK, Kosiniski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide 1993. Boston, MA: The Health Institute, New England Medical Centre; 1993.
69. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HCJ, Perrillo RP et al. Assessing health-related quality of life in chronic hepatitis using the sickness impact profile. Clin Ther 1994;16:334-43.
70. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-12.
71. Goh J, Coughlan B, Quinn J, O'Keane JC, Crowe J. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1999;11:833-8.
72. Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001;96:579-83.
73. Foster GR. Hepatitis C virus infection: Quality of life and side effects of treatment. J Hepatol 1999;31 Suppl 1:250-4.
74. Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis 1997;42:2482-6.
75. Neary MP, Cort S, Bayliss MS, Ware JE. Sustained virological response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 1999; 19 Suppl 1:77-86.
76. Drummond M, O'Brien B, Stoddart GL., Torrance GW. Methods for the Economic Evaluation of Health Care Programmes 1999. Oxford: Oxford University Press; 1999.
77. Leal P, Stein K, Rosenberg W. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users? J Med Screen 1999;6:124-31.
78. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: A rapid and systematic review. Health Technol Assess 2000;4(33):1-67.
79. Serfaty M, Lawrie A, Smith B, Brind A, Watson J, Gilvarry E et al. Risk factors and medical follow up of drug users tested for hepatitis C - Can the risk of transmission be reduced? Drug Alcohol Rev 1997;16:339-47.
80. The Governments Actuaries Department. Interim life tables: Expectation of life, Great Britain - Based on data for the years 1997-1999. URL: http://www.gad.gov.uk/policy_and_stats/life_tables.htm
81. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
82. Bacosi M, Patsouri M, Miglioresi L, Patrizi F, Russo F, Ricci GL. Combined treatment of HCV infection: Is there a need for meta-analysis? Hepatol Res 2001;20:359-71.
83. Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: Systematic review of randomised trials. BMJ 2001;323:1151-5.
84. Leal P, Stein K. Cost Utility of Screening for HCV in Intravenous Drug Users and GUM Clinic Attenders 1998. Bristol, NHS Executive (South West). Report to the South West Development and Evaluation Committee; 1998.
85. Ishizuka M. Economic evaluation of health care program for hepatitis C virus antibody screening. Nippon Koshu Eisei Zasshi 1999;46:447-65.
86. Rotily M, Loubiere S, Nixon J, Bourliere M, Halfon P, Moatti JP. Faut-il depister l'hepatite C? Analyse socio-economique de differentes strategies de depistage de l'hepatite chronique C dans la population francaise. [Should hepatitis C be screened? Socioeconomic analysis of different screening strategies for chronic hepatitis C in the French population]. Gastroenterol Clin Biol 1997;21:S33-40.
87. Lapane KL, Jakiche AF, Sugano D, Weng CS, Carey WD. Hepatitis C infection risk analysis: Who should be screened? Comparison of multiple screening strategies based on the National Hepatitis Surveillance Program. Am J Gastroenterol 1998;93:591-6.
88. Kaur S, Rybicki LB, Bacon BR, Gollan JL, Rustgi VK, Carey WD. Performance characteristics and results of a large-scale screening programme for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C: Results of the National Hepatitis Screening Survey. Hepatology 1996;24:979-86.
89. Fischer LR, Tope DH, Conboy KS, Hedblom BD, Ronberg E, Shewmake DK et al. Screening for hepatitis C virus in a health maintenance organization. Arch Intern Med 2000;160:1665-73.
90. Desenclos JC, Dubois F, Mariotte N, Goudeau A. Faut-il depister l'hepatite C? Analyse des strategies de depistage oriente de l'infection par le virus de l'hepatite C. [Should hepatitis C be screened? Analysis of oriented screening strategies for hepatitis C virus infection]. Gastroenterol Clin Biol 1997;21:S25-32.
91. Perez P. Efficacite et impact psychosocial du depistage de l'hepatite C. Gastroenterol Clin Biol 1997;20:S140-7.
92. Roque I, Goria O, Merle V, Bord S, Janvresse C, Czernichow P et al. Depistage de l'hepatite C au Centre de Depistage Anonyme et Gratuit de Rouen. Gastroenterol Clin Biol 1999;23:1397-8.
93. Muir Gray JA. London: Churchill Livingstone; 1997.
94. Cook P, McVeigh J, Syed Q, Mutton K, Bellis M. Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment. Addiction 2001;96:1787-97.
95. Vidal-Trecan G, Coste J, Varescon-Pousson I, Christoforov B, Boissonnas A. HCV status knowledge and risk behaviours amongst intravenous drug users. Eur J Epidemiol 2000;16:439-45.
96. Malliori M, Sypsa V, Psichogiou M, Touloumi G, Skoutelis A, Tassopoulos M. A survey of bloodborne viruses and associated risk behaviours in Greek prisons. Addiction 1998;93:243-51.
97. Ompad D, Fuller C, Vlahov D, Thomas D, Johnson L, Harrington C, et al. Lack of behaviour change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland 2000. Paper presented at the
98. Wenger NS, Linn LS, Epstein M, Shapiro MF. Reduction of high-risk sexual-behavior among heterosexuals undergoing HIV antibody testing - A randomized clinical trial. Am J Public Health 1991;81:1580-5.
99. Greenfield L, Bigelow GE, Brooner RK. Validity of intravenous drug-abusers self-reported changes in HIV high-risk drug-use behaviors. Drug Alcohol Depend 1995;39:91-8.
100. Weinstein ND, Rothman AJ, Nicolich M. Use of correlational data to examine the effects of risk perceptions on precautionary behavior. Psychol Health 1998;13:479-501.
101. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: An analysis of the literature. J Viral Hepatitis 2001;8:87-95.
102. Roche Diagnostics Ltd. COBAS AMPLICOR Hepatitis C Virus Test, Version 2.0 (Rev 3.0). Lewes, East Sussex: Roche Diagnostics Ltd; 1999.
103. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: Results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the study of the Liver (AFEF). Hepatology 2000;32:477-81.
104. Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000;14:543-8.
105. Smyth BP, Keenan E, O'Connor JJ. Assessment of hepatitis C infection in injecting drug users attending an addiction treatment clinic. Ir J Med Sci 2000;169:129-32.
106. Jowett SL, Agarwal K, Smith BC, Craig W, Hewett M, Bassendine DR et al. Managing chronic hepatitis C acquired through intravenous drug use. QJM 2001;153-8.
107. Carruthers S, Loxley W. Hepatitis C and young drug users: Are they about to join the epidemic? Aust J Public Health 1995;19:421-4.
108. Sahajian F, Bailly F, Caillat-Vallet E, Pradat P, Excler G, Sepetjan M et al. Medical follow-up of patients with positive serology for hepatitis C virus. Gastroenterol Clin Biol 2001;25:262-7.
109. Di Bisceglie AM. Hepatitis C. Lancet 1998;351:351-5.
110. Young TA, Longworth L, Ratcliffe J. Economic Evaluation of the Liver Transplant Programme in England and Wales: Survival on the Waiting List, Post Transplant, and Estimated Survival in the Absence of Transplantation. Final Report to the Department of Health. Uxbridge: Brunel University; 2000.
111. Barbaro G, Di Lorenzo G, Belloni G, Ferrari L, Paiano A, Belloni G et al. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: An Italian multicentre, randomized, controlled clinical study. Am J Gastroenterol 1998;93:2445-51.
112. Netten A, Rees T, Harrison G. Unit Costs of Health and Social Care 2000. Canterbury: Personal Social Services Research Unit, University of Kent; 2001.
113. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary 42. London: BMA and RPSBG; 2001.
114. Cotler SJ, Patil R, McNutt RA, Speroff T, Banaad-Omiotek G, Ganger DR et al. Patients' values for health states associated with hepatitis C and physicians' estimates of those values. Am J Gastroenterol 2001;96:2730-6.
115. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;27:855-65.
116. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
117. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-88.
118. Department of Health. NHS Reference Costs. London: Department of Health; 2000.
119. Fontana RJ, Moyer CA, Sonnad S, Lok ASF, Sneed PN, Walsh J et al. Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol 2001;96:170-8.
120. Foster GR, Goldin RD, Main J, Murray-Lyon IM, Hargreaves S, Thomas HC. Management of chronic hepatitis C: Clinical audit of biopsy based management algorithm. BMJ 1997;315:453-8.
121. Davis GL, Esteban MR, Rustgi V, Hoefs J, Gordon SC. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
122. Prochaska JA, DiClemente CC. Stages and processes of self-change in smoking: Toward an integrative model of change. J Consult Clin Psychol 1983;51:390-5.
123. Hartnoll R, Lewis R, Mitcheson M, Bryer S. Estimating the prevalence of opioid dependence. Lancet 1985;1(8422):203-5.
124. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001;345:211-15.
125. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001;345:215-17.
126. Cheng SJ, Bonis PA, Lau J, Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta-analysis of controlled and uncontrolled trials. Hepatology 2001;33:231-40.
127. Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. JAMA 2001;385:193-9.
128. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
129. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
130. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
131. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK et al. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000;68:556-67.
132. Zeuzem S, Hermann E, Lee JH, Fricke J, Neumann AU, Modi M et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001;120:1438-47.